Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase [2]

Blood

Volumn 101, Issue 11, 2003, Pages 4642-4643

  Rumpel, Mathias ^b   Friedrich, Thomas ^b   Deininger, Michael W N ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

ANGIOGENESIS; BLOOD LEVEL; BONE MARROW; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 0038382050     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol. 2000;157:15-19.
2. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.
3. Verstovsek S, Kantarjian H, Manshouri T, et al. Prognostic significance of cellular vascular endothellal growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.
4. Mayerhofer M, Valent P, Sperr WR, Griffin JD, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1 alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002;100:3767-3775.
5. Ebos JM, Tran J, Master Z, et al. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res. 2002;1:89-95.
6. Larson RA for the IRIS study group. Imatinib (STI571, Gleevec) as initial therapy for patients with newly diagnosed Ph+ chronic myelold leukemia (CML): results from a randomized phase III study vs interferon-alpha + cytarabine (IFN+AraC) [abstract]. Blood. 2002;100:4a.
7. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
8. Leveen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev. 1994;8:1875-1887.
9. Karp JE, Gojo I, Gocke CD, et al. Timed sequential therapy (TST) of relapsed and refractory adult acute myelogenous leukemia (AML) with the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab [abstract]. Blood. 2002;100:198a.
10. Stopeck A, Karp JE, Silverman L, et al. Results of a phase II study of SU5416 in the treatment of patients with myeloproliferative disorders: evidence for in vivo target inhibition [abstract]. Blood. 2001;98:632a.